SBK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL12743053	0.62	2/20
SCHEMBL1134152	0.55	2/20
Afatinib (SCHEMBL185621)	1.00	1/20
Afatinib (SCHEMBL185786)	1.00	1/20
Afatinib (SCHEMBL231072)	1.00	1/20
Afatinib (SCHEMBL231073)	1.00	1/20
Afatinib (SCHEMBL232772)	1.00	1/20
Afatinib (SCHEMBL2269415)	1.00	1/20
Afatinib (SCHEMBL2865630)	1.00	1/20
Afatinib (SCHEMBL2865634)	1.00	1/20
SCHEMBL1191232	0.92	1/20
SCHEMBL1190862	0.89	1/20
SCHEMBL1190864	0.89	1/20
SCHEMBL1190866	0.89	1/20
SCHEMBL1190947	0.89	1/20
SCHEMBL1190948	0.89	1/20
SCHEMBL1190951	0.89	1/20
SCHEMBL1190329	0.88	1/20
SCHEMBL1190332	0.88	1/20
SCHEMBL1190335	0.88	1/20

Clinical trials — most relevant to SBK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA	PHASE4	COMPLETED
Sirolimus Treatment for Refractory PRCA	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI	PHASE1/PHASE2	UNKNOWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer	PHASE1/PHASE2	COMPLETED
Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19	PHASE2	UNKNOWN
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	PHASE1	ACTIVE_NOT_RECRUITING
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors	PHASE1	COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Exercise in Type 1 Diabetes Mellitus	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SBK1 binder may also engage these)

Protein	Name	Similarity
Q9Z335	—	1.000	Q9Z335 →
Q8QZX0	—	0.998	Q8QZX0 →
PKN1	Serine/threonine-protein kinase N1	0.966	landscape →
Q504Y2	—	0.961	Q504Y2 →
Q4FZD7	—	0.961	Q4FZD7 →
A1A4I4	—	0.960	A1A4I4 →
Q96G42	—	0.960	Q96G42 →
Q5RJI4	—	0.958	Q5RJI4 →
Q8N1F8	—	0.955	Q8N1F8 →
P70268	—	0.955	P70268 →
PML	Protein PML	0.955	landscape →
Q8BNW9	—	0.953	Q8BNW9 →
Q6UXT9	—	0.953	Q6UXT9 →
Q69Z89	—	0.953	Q69Z89 →
A7MCT6	—	0.952	A7MCT6 →
PLK3	Serine/threonine-protein kinase PLK3	0.952	landscape →
WEE1	Wee1-like protein kinase	0.951	landscape →
Q63433	—	0.951	Q63433 →
Q9D6E4	—	0.951	Q9D6E4 →
Q8BKN6	—	0.951	Q8BKN6 →
A4D2P6	—	0.950	A4D2P6 →
Q9NRU3	—	0.950	Q9NRU3 →
D3ZRW8	—	0.950	D3ZRW8 →
Q5QP82	—	0.950	Q5QP82 →
STK35	Serine/threonine-protein kinase 35	0.949	landscape →
P97260	—	0.949	P97260 →
Q60806	—	0.949	Q60806 →
Q5EBM0	—	0.949	Q5EBM0 →
Q9HBU6	—	0.949	Q9HBU6 →
Q9WTY2	—	0.949	Q9WTY2 →